Invitrogen expands its offering
Invitrogen Corporation, of Carlsbad, California, has launched its Omnia Kinase Assays for the rapid, homogenous and sensitive detection of enzymatic activity under physiological ATP concentrations.
Invitrogen Corporation, of Carlsbad, California, has launched its Omnia Kinase Assays for the rapid, homogenous and sensitive detection of enzymatic activity under physiological ATP concentrations.
Scientists can simply mix reagents, read real-time fluorescent signals and get results in under an hour, the company says. Omnia offers a simple mix and read procedure, streamlining assay set-up and speeding data collection.
The company has also made available Bulk IGF-I Product (BIP) for use in large-scale manufacturing and process development applications.
IGF-I is an insulin-like growth factor used to supplement serum-free culture media. The new bulk packaging eliminates the need for multiple vials and reduces the potential risks of compromised product. In addition, because BIP is animal-origin free, regulatory approval is simplified.